Soleno Therapeutics (SLNO) Stock Forecast & Price Target

Compare

890 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SLNO Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Soleno

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SLNO Stock 12 Month Forecast

Average Price Target

$105.13

▲(147.48% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Soleno Therapeutics in the last 3 months. The average price target is $105.13 with a high forecast of $123.00 and a low forecast of $60.00. The average price target represents a 147.48% change from the last price of $42.48.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","124":"$124","63.25":"$63.3","83.5":"$83.5","103.75":"$103.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":123,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$123.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$105.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,63.25,83.5,103.75,124],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.3,52.199999999999996,58.099999999999994,64,69.9,75.8,81.7,87.6,93.5,99.4,105.3,111.2,117.10000000000001,{"y":123,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.3,50.825384615384614,55.35076923076923,59.87615384615384,64.40153846153845,68.92692307692307,73.45230769230768,77.97769230769231,82.50307692307692,87.02846153846153,91.55384615384615,96.07923076923076,100.60461538461539,{"y":105.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.3,47.35384615384615,48.40769230769231,49.46153846153846,50.51538461538461,51.56923076923077,52.62307692307692,53.676923076923075,54.730769230769226,55.784615384615385,56.83846153846154,57.892307692307696,58.94615384615385,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$123.00

Average Price Target$105.13

Lowest Price Target$60.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Derek Archila

Wells Fargo

$106

Buy

149.53%

Upside

Reiterated

01/13/26

Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo

Kristen Kluska

Cantor Fitzgerald

$123

Buy

189.55%

Upside

Reiterated

01/13/26

Cantor Fitzgerald Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)

Brian Skorney

Robert W. Baird

$121→$107

Buy

151.88%

Upside

Reiterated

01/13/26

Soleno Therapeutics price target lowered to $107 from $121 at BairdSoleno Therapeutics price target lowered to $107 from $121 at Baird

Kalpit Patel

Wolfe Research

$75→$60

Buy

41.24%

Upside

Reiterated

01/12/26

Soleno Therapeutics price target lowered to $60 from $75 at Wolfe ResearchSoleno Therapeutics price target lowered to $60 from $75 at Wolfe Research

Kate Dellorusso

LifeSci Capital

$110→$100

Buy

135.40%

Upside

Reiterated

01/12/26

Soleno Therapeutics: Sustained U.S. Vykat XR Outperformance and European Upside Support Buy Rating and $100 Target

Ram Selvaraju

H.C. Wainwright

$110

Buy

158.95%

Upside

Reiterated

11/10/25

Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating

Tyler Van Buren

TD Cowen

$115→$120

Buy

182.49%

Upside

Reiterated

11/07/25

James Condulis

Stifel Nicolaus

$115

Buy

170.72%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Paul Choi

Goldman Sachs

$125

Buy

194.26%

Upside

Initiated

10/07/25

Buy Rating for Soleno Therapeutics: Strong Market Potential and Growth Opportunities with Vykat XR

Yasmeen Rahimi

Piper Sandler

$145

Buy

241.34%

Upside

Reiterated

10/03/25

Piper Sandler Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Leland Gershell

Oppenheimer

$110

Buy

158.95%

Upside

Reiterated

08/25/25

Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (NASDAQ: SLNO) and Hinge Health, Inc. Class A (NYSE: HNGE)

Debjit Chattopadhyay

Guggenheim

$97→$106

Buy

149.53%

Upside

Reiterated

08/06/25

Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

Yale Jen

Laidlaw

$75→$105

Buy

147.18%

Upside

Reiterated

03/27/25

Soleno Therapeutics price target raised to $105 from $75 at LaidlawSoleno Therapeutics price target raised to $105 from $75 at Laidlaw

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Derek Archila

Wells Fargo

$106

Buy

149.53%

Upside

Reiterated

01/13/26

Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo

Kristen Kluska

Cantor Fitzgerald

$123

Buy

189.55%

Upside

Reiterated

01/13/26

Cantor Fitzgerald Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)

Brian Skorney

Robert W. Baird

$121→$107

Buy

151.88%

Upside

Reiterated

01/13/26

Soleno Therapeutics price target lowered to $107 from $121 at BairdSoleno Therapeutics price target lowered to $107 from $121 at Baird

Kalpit Patel

Wolfe Research

$75→$60

Buy

41.24%

Upside

Reiterated

01/12/26

Soleno Therapeutics price target lowered to $60 from $75 at Wolfe ResearchSoleno Therapeutics price target lowered to $60 from $75 at Wolfe Research

Kate Dellorusso

LifeSci Capital

$110→$100

Buy

135.40%

Upside

Reiterated

01/12/26

Soleno Therapeutics: Sustained U.S. Vykat XR Outperformance and European Upside Support Buy Rating and $100 Target

Ram Selvaraju

H.C. Wainwright

$110

Buy

158.95%

Upside

Reiterated

11/10/25

Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating

Tyler Van Buren

TD Cowen

$115→$120

Buy

182.49%

Upside

Reiterated

11/07/25

James Condulis

Stifel Nicolaus

$115

Buy

170.72%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Paul Choi

Goldman Sachs

$125

Buy

194.26%

Upside

Initiated

10/07/25

Buy Rating for Soleno Therapeutics: Strong Market Potential and Growth Opportunities with Vykat XR

Yasmeen Rahimi

Piper Sandler

$145

Buy

241.34%

Upside

Reiterated

10/03/25

Piper Sandler Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Leland Gershell

Oppenheimer

$110

Buy

158.95%

Upside

Reiterated

08/25/25

Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (NASDAQ: SLNO) and Hinge Health, Inc. Class A (NYSE: HNGE)

Debjit Chattopadhyay

Guggenheim

$97→$106

Buy

149.53%

Upside

Reiterated

08/06/25

Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

Yale Jen

Laidlaw

$75→$105

Buy

147.18%

Upside

Reiterated

03/27/25

Soleno Therapeutics price target raised to $105 from $75 at LaidlawSoleno Therapeutics price target raised to $105 from $75 at Laidlaw

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Soleno Therapeutics

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+77.36%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +77.36% per trade.

1 Year

Kristen KluskaCantor Fitzgerald

Success Rate

6/11 ratings generated profit

Average Return

+154.25%

reiterated a buy rating 6 days ago

Copying Kristen Kluska's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +154.25% per trade.

2 Years

xxx

Success Rate

8/22 ratings generated profit

Average Return

+183.11%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of +183.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLNO Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SLNO has received 18 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. SLNO average Analyst price target in the past 3 months is 105.13.

Each month's total comprises the sum of three months' worth of ratings.

SLNO Financial Forecast

SLNO Earnings Forecast

Next quarter’s earnings estimate for SLNO is $0.64 with a range of $0.45 to $1.01. The previous quarter’s EPS was $0.47. SLNO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SLNO has Performed in-line its overall industry.

SLNO Sales Forecast

Next quarter’s sales forecast for SLNO is $84.75M with a range of $73.84M to $91.60M. The previous quarter’s sales results were $66.02M. SLNO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SLNO has Performed in-line its overall industry.

SLNO Stock Forecast FAQ

What is SLNO’s average 12-month price target, according to analysts?

Based on analyst ratings, Soleno Therapeutics Inc’s 12-month average price target is 105.13.

What is SLNO’s upside potential, based on the analysts’ average price target?

Soleno Therapeutics Inc has 147.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SLNO a Buy, Sell or Hold?

Soleno Therapeutics Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Soleno Therapeutics Inc’s price target?

The average price target for Soleno Therapeutics Inc is 105.13. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $123.00 ,the lowest forecast is $60.00. The average price target represents 147.48% Increase from the current price of $42.48.

What do analysts say about Soleno Therapeutics Inc?

Soleno Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of SLNO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

SLNO Analyst Ratings

SLNO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Soleno Therapeutics

SLNO Analyst Recommendation Trends

SLNO Financial Forecast

SLNO Earnings Forecast

SLNO Sales Forecast

SLNO Stock Forecast FAQ

Detailed List of Analyst Forecasts